B-Cell Non-Hodgkin Lymphoma (NHL) Marketed and Pipeline Drugs Assessment Dominated by Roche – GlobalData Plc
There are 1.7 million diagnosed prevalent cases of B-cell non-Hodgkin’s lymphoma (B-cell NHL) in the 16 countries covered in GlobalData’s epidemiology B-Cell Non-Hodgkin Lymphoma (NHL) marketed and pipeline drugs assessment forecast. Due to its high prevalence rates and the global availability of the latest treatment options, guidelines for B-cell NHL are well established. China, the US, and the UK have the most recently updated guidelines, provided by the National Comprehensive Cancer Network and the National Cancer Institute (US). B-cell NHL generally arises in the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen, and can disseminate to involve distant sites such as the lung or brain in the later stages of the disease. NHLs are further categorized into indolent or aggressive prognostic subtypes, which further influence outcomes and treatment decisions.
For more insights on the B-cell NHL marketed and pipeline drugs assessment market, download a free sample report
B-cell NHL Marketed and Pipeline Drugs Assessment Market FAQs
- What are the key mechanisms of action for B-Cell NHL marketed drugs?
Some of the key mechanisms of action for B-Cell NHL marketed drugs are peptide and peptide inhibitor, genes, nucleic acids & related component inhibitor, protein and peptide activator, enzyme inhibitor, cytotoxic cell, receptor agonist, receptor antagonist.
- What are the key routes of administration for B-Cell NHL marketed drugs?
The key routes of administration for B-Cell NHL marketed drugs are injection, oral, topical, and suppository.
- What are the key molecule types for B-Cell NHL marketed drugs?
The key molecule types for B-Cell NHL marketed drugs are small molecule and biologics.
- What are the key mechanisms of action for B-Cell NHL pipeline drugs?
Some of the key mechanisms of action for B-Cell NHL pipeline drugs are cytotoxic to cell, enzyme inhibitor, protein & peptide inhibitor, receptor agonist, receptor antagonist, and antigen inhibitor.
- What are the key routes of administration for B-Cell NHL pipeline drugs?
The key routes of administration for B-Cell NHL pipeline drugs are injection, oral, topical, suppository, and inhalational.
- What are the key molecule types for B-Cell NHL pipeline drugs?
The key molecule types in B-Cell NHL pipeline drugs are biologics, oligonucleotide, and small molecule.
- Who are the top clinical trial sponsors for the B-Cell NHL marketed and pipeline drugs market?
Some of the top clinical trial sponsors for the B-Cell NHL marketed and pipeline drugs market are F.Hoffmann-La Roche Ltd, University of Texas MD Anderson Cancer Center, National Cancer Institute US, Johnson & Johnson, Gilead Sciences Inc, Celgene Corp, BeiGene Ltd, Novartis AG, and AbbVie Inc.
For more queries on B-Cell NHL marketed and pipeline drugs market, view free sample report
B-Cell NHL Marketed and Pipeline Drugs Market – Top Clinical Trial Sponsors
Some of the top clinical trial sponsors in the B-Cell NHL marketed and pipeline drugs market are F.Hoffmann-La Roche Ltd, University of Texas MD Anderson Cancer Center, National Cancer Institute US, Johnson & Johnson, Gilead Sciences Inc, Celgene Corp, BeiGene Ltd, Novartis AG, and AbbVie Inc among others.
Get sample report for more insights on B-Cell NHL marketed and pipeline drugs sponsors
B-Cell NHL Marketed and Pipeline Drugs Market Highlights
- The peptide and peptide inhibitor segment was the most common mechanism of action for B-Cell NHL marketed drugs.
- The key routes of administration for B-Cell NHL marketed drugs are injection, oral, topical, and suppository. Most conventional marketed drugs available for B-Cell NHL are intravenous therapies.
- The key molecule types in the market are small molecule and biologics. The marketed drugs space for B-Cell NHL is dominated by the small molecule segment.
- Cytotoxic to cell lead the MoA segment in the B-Cell NHL pipeline drugs market.
- The key routes of administration for B-Cell NHL pipeline drugs are injection, oral, topical, inhalational, and suppository. Most pipeline drugs for B-cell NHL are injection therapies followed by oral drugs.
- The B-Cell NHL pipeline drugs comprise mostly biologics, small molecules, and oligonucleotide. Most More than 60% of the B-cell NHL pipeline is dominated by biologic molecules.
For additional highlights on the B-cell NHL marketed and pipeline drugs market, grab your sample report copy!
Related Reports
Table of Contents
1 Preface
1.1 Contents
1.2 Report Scope
1.3 List of Tables and Figures
1.4 Abbreviations
2 Key Findings
3 Disease Landscape
3.1 Disease Overview
3.2 Epidemiology Overview
3.3 Treatment Overview
4 Marketed Drugs Assessment
4.1 Leading Marketed Drugs
4.2 Overview by Mechanism of Action
4.3 Overview by Route of Administration
4.4 Marketed Drugs Profiles and Sales Forecasts
5 Pricing and Reimbursement Assessment
5.1 Manufacturer Price
5.2 Time to Pricing and Reimbursement
6 Pipeline Drugs Assessment
6.1 Phase III Pipeline Drugs
6.2 Overview by Development Stage
6.3 Overview by Molecule Type
6.4 Overview by Mechanism of Action
6.5 Overview by Route of Administration
6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
6.7 Therapy Area and Indication-specific PTSR and LoA
7 Clinical Trials Assessment
7.1 Historical Overview
7.2 Overview by Phase
7.3 Overview by Status
7.4 Overview by Phase for Ongoing and Planned Trials
7.5 Trials with Virtual Components
7.6 Geographic Overview
7.7 Single-Country and Multinational Trials by Region
7.8 Top 20 Sponsors with Breakdown by Phase
7.9 Top 20 Sponsors with Breakdown by Status
7.10 Overview by Endpoint Status
7.11 Overview by Race and Ethnicity
7.12 Enrollment Data
7.13 Top 20 countries for Trial Sites
7.14 Top 20 Sites Globally
7.15 Feasibility Analysis – Geographic Overview
7.16 Feasibility Analysis – Benchmark Models
8 Deals Landscape
8.1 Mergers, Acquisitions, and Strategic Alliances by Region
8.2 Recent Mergers, Acquisitions, and Strategic Alliances
9 Commercial Assessment
9.1 Key Market Players
10 Future Market Catalysts
11 Appendix
11.1 Methodology
11.2 Methodology – Sales Forecast
11.3 Methodology – Pricing and Reimbursement
11.4 Methodology – PTSR and LoA Analysis
11.5 About the Authors
11.6 Contact Us
11.7 Disclaimer
About us
GlobalData is a leading provider of data, analytics, and insights on the world’s largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision-makers to predict and navigate the future. GlobalData’s mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on us for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.
Media Contacts
GlobalData
Mark Jephcott
Head of PR EMEA
+44 (0)207 936 6400
Contact Information:
GlobalData Mark Jephcott Head of PR EMEA [email protected] cc: [email protected] +44 (0)207 936 6400
Tags:
Reportedtimes, Extended Distribution, iCN Internal Distribution, Research Newswire, English